These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18666039)

  • 21. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
    Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
    Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A surview of recent patents on anti-infective therapy for Clostridium difficile.
    Soliman GS; Saleib B; Scholand SJ
    Recent Pat Antiinfect Drug Discov; 2013 Aug; 8(2):139-49. PubMed ID: 23879822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pseudomembraneous colitis caused by a toxin B-positive and a toxin A-negative strain of Clostridium difficile].
    Jakobsen L; Tvede M
    Ugeskr Laeger; 2006 Apr; 168(17):1634-5. PubMed ID: 16674873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic absorption of oral vancomycin in patients with Clostridium difficile infection.
    Rao S; Kupfer Y; Pagala M; Chapnick E; Tessler S
    Scand J Infect Dis; 2011 May; 43(5):386-8. PubMed ID: 21198337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clostridium difficile infection.
    Kelly CP; LaMont JT
    Annu Rev Med; 1998; 49():375-90. PubMed ID: 9509270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clostridium difficile associated diarrhea: reliable therapy with vancomycin capsules].
    MMW Fortschr Med; 2012 Sep; 154(16):64-5. PubMed ID: 23045940
    [No Abstract]   [Full Text] [Related]  

  • 27. Failure of intravenous linezolid to treat Clostridium difficile associated diarrhea.
    Lazzarini L; De Lalla F
    J Chemother; 2003 Jun; 15(3):299-300. PubMed ID: 12868561
    [No Abstract]   [Full Text] [Related]  

  • 28. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.
    Norén T; Wullt M; Akerlund T; Bäck E; Odenholt I; Burman LG
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3028-32. PubMed ID: 16940098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea.
    Parkes GC; Sanderson JD; Whelan K
    Lancet Infect Dis; 2009 Apr; 9(4):237-44. PubMed ID: 19324296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control.
    DuPont HL; Garey K; Caeiro JP; Jiang ZD
    Curr Opin Infect Dis; 2008 Oct; 21(5):500-7. PubMed ID: 18725800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment strategies for recurrent and refractory Clostridium difficile-associated diarrhea.
    Stepan C; Surawicz CM
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):295-305. PubMed ID: 19072422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nosocomial diarrhoea in adult medical patients: the role of Clostridium difficile in a North Italian acute care teaching hospital.
    Sansone S; Aschbacher R; Staffler M; Bombonato M; Girardi F; Larcher C; Wiedermann CJ
    J Prev Med Hyg; 2009 Jun; 50(2):117-20. PubMed ID: 20099443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fidaxomicin: a novel macrolide antibiotic for Clostridium difficile infection.
    Chahine EB; Sucher AJ; Mantei K
    Consult Pharm; 2014 Sep; 29(9):614-24. PubMed ID: 25203410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.
    Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L
    Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New agents for Clostridium difficile-associated disease.
    Guiles J; Critchley I; Sun X
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1671-83. PubMed ID: 18922104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clostridium difficile-associated disease. Epidemiology, morbidity, mortality, and methods for control.
    Miller MA
    Postgrad Med; 2001 Feb; 109(2 Suppl):39-42. PubMed ID: 19667556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clostridium difficile-associated colitis.
    Hull MW; Beck PL
    Can Fam Physician; 2004 Nov; 50():1536-40, 1543-5. PubMed ID: 15597970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudomembranous colitis in children.
    Brook I
    J Gastroenterol Hepatol; 2005 Feb; 20(2):182-6. PubMed ID: 15683418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Clostridium difficile-associated disease: old therapies and new strategies.
    Aslam S; Hamill RJ; Musher DM
    Lancet Infect Dis; 2005 Sep; 5(9):549-57. PubMed ID: 16122678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metronidazole resistance in Clostridium difficile.
    Johnson S; Sanchez JL; Gerding DN
    Clin Infect Dis; 2000 Aug; 31(2):625-6. PubMed ID: 10987742
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.